Targeted treatment options for advanced lung cancer include single-agent gefitinib, single-agent crizotinib, darafenib combined with trametinib, etc. Specific options need to be chosen according to the type of gene mutation and cannot be generalized. Lung cancer in advanced stage can have different types of gene mutation, such as EGFR mutation, ALK mutation, BRAF mutation, etc. According to different types of gene mutation, different targeted treatment programs can be chosen. EGFR gene mutation can choose single-agent gefitinib, single-agent ositinib and other programs, ALK mutation can choose single-agent crizotinib, single-agent alectinib and other programs for treatment, and BRAFV600E mutation can choose dalafenib combined with trametinib program. In addition to the above targeted therapeutic programs, patients with advanced lung cancer may also choose other targeted therapeutic programs due to other gene mutations, for example, single-agent entrectinib program can be chosen for ROS1 gene mutation. Patients with advanced lung cancer are recommended to seek medical treatment in time, communicate with the competent doctor according to the actual situation, and choose the suitable targeted therapy program for themselves.